Date: 2011-12-12
Type of information: Grant
Company: CYTOO (France), Cenix BioScience (Germany), three academic partners
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €4 million
Funding type: grant
Planned used: CYTOO, a company that specializes in micropattern-enhanced cell-based assays, has teamed up with Cenix BioScience, a pioneer in developing industrial high-content screening applications of RNAi, and three European academic partners to challenge the current limits of high throughput (HT) RNAi screening in cultured cells. The SME-driven project, coordinated by CYTOO, aims to combine HT applications of RNAi with an emerging new technology for normalizing cultured cells’ behaviour by growing them on adhesive micropatterns. The MEHTRICS consortium has been awarded a 4 million Euro research grant over 3 years under the European Commission’s Seventh Framework Program.
Others: The three academic partners come from the Heidelberg, Germany-based Bioquant/Heidelberg University teams of Drs. Ulrich Schwarz and Holger Erfle, the Lausanne, Switzerland-based EPFL team of Dr. Pierre Gönczy and the Vilnius, Lithuania-based Institute FTMC team of Dr. Ramunas Valiokas. The consortium’s administrative and financial activities will be coordinated by VITAMIB, a well-established French SME specialised in design and management of collaborative research projects.
Therapeutic area: Technology - Services
